Selected EU nations suspend Moderna’s vaccine for young adults - Kalkine Media

October 07, 2021 08:19 PM AEDT | By Tripti Joshi
Follow us on Google News:

Highlights 

  • Moderna’s COVID-19 vaccine suspended in some counties for younger adults due to some rare side effects.
  • Sweden, Norway, and Denmark paused Moderna’s COVID-19 vaccine and urged younger adults to take Pfizer/BioNTech shot.
  • On 5 October, the European regulator approved the booster shot of Moderna’s COVID-19 vaccine for 12 years or older people.

Few European nations have temporary banned Moderna Inc’s (NASDAQ:MRNA) COVID-19 vaccine in younger adults after appearance of some rare heart related side effects especially after the second shot. Following the suspension news, Moderna’s shares fell as much as 8.94% on 6 October 2021 on NASDAQ.

In January 2021, the European Medicines Agency (EMA) gave green light to Moderna’s COVID-19 vaccine for people 18 years and over. In July, the vaccine was given emergency use authorisation for children aged 12-17 year.   

Scandinavian agencies suspend Moderna’s vaccine

On 6 October 2021, Scandinavian authorities halted administration of COVID-19 vaccine of Moderna in young adults due to an increased risk of inflammation of the heart muscle.  

The Public Health Agency of Sweden had terminated Moderna’s COVID-19 vaccine for those individuals under 30 years. The agency highlighted that the temporary halt would be initially in force until 1 December 2021.

Furthermore, the agency highlighted that, the risk is more prevalent among young men and boys and seems especially related to the second shot of the vaccine.

RELATED ARTICLE: Tips for investing in COVID-19 vaccines developing stocks

Moderna’s COVID-19 vaccine suspended due to side effects

Source: © Ekahardiwito | Megapixl.com

Norway and Denmark to continue using Pfizer/BioNTech vaccine

Norway and Denmark also recommended a halt for people under 18 years. Denmark highlighted that the country will continue to use the vaccine developed by Pfizer-BioNTech as its main choice for people aged 12-17 years. Besides, Norway urged people who are under 30 to get the Pfizer-BioNTech’s vaccine instead.

The COVID-19 vaccines developed by Moderna and Pfizer-BioNTech rely on messenger RNA (mRNA) technology to induce an immune reaction against novel coronavirus.

RELATED READ: Role of mRNA vaccines in combating COVID-19: Pros & Cons

Moderna’s booster shot got EMA green light

On 5 October 2021, the European Medicines Agency (EMA) approved the use of a booster shot or third dose of Moderna COVID-19 vaccine for people (12 years of age or older) having severely deteriorated immune system. Moderna highlighted that several studies have demonstrated the benefit of a booster shot of COVID-19 vaccine in people having compromised immune system.

RELATED READ: COVID-19 booster shot for immunocompromised people: are there any additional risks?

EMA approves Moderna’s booster shot

Source: © Demidovichphotostock | Megapixl.com

Bottom Line

After witnessing the heart related side effects post administration of Moderna’s COVID-19 vaccine in younger adults, selected European nations have recommended to use Pfizer-BioNTech’s COVID-19 vaccine for adults under 30 year.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.



Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK